NASDAQ$AHCO
AdaptHealth Corp. · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
AdaptHealth's Q2 2023 results showed revenue growth and solid performance in core Sleep and Respiratory product lines, with significant cash generation and progress in cost-management.
AdaptHealth Corp. reported a 9.0% increase in net revenue to $793.3 million for Q2 2023, driven by strength in Sleep and Respiratory product lines. Net income attributable to AdaptHealth Corp. remained consistent at $14.0 million. The company is updating its financial guidance for fiscal year 2023.
- Net revenue increased by 9.0% to $793.3 million.
- Non-acquired net revenue growth was 8.7%.
- Net income attributable to AdaptHealth Corp. was $14.0 million.
- Adjusted EBITDA increased by 14.0% to $171.0 million.
Headline financials
Revenue & EPS history
AdaptHealth · Revenue · Quarterly
$793M
Forward guidance
The Company is updating previous financial guidance for fiscal year 2023 as follows: •Net revenue of $3.16 to $3.20 billion, from $3.16 to $3.24 billion •Adjusted EBITDA of $650 to $680 million, from $650 to $710 million •Total capital expenditures representing 10-12% of net revenue, unchanged •Free cash flow representing 3-4% of net revenue, unchanged
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+0.6%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+1.6%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+34.6%
Q4 2023
Best reaction
-27.9%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -10.0% | -13.4% | -25.6% | |
| Q4 2025 | -14.2% | -11.1% | +10.9% | |
| Q3 2025 | +17.2% | +4.5% | +3.2% | |
| Q1 2025 | +1.7% | -1.4% | +3.7% | |
| Q4 2024 | +24.4% | +33.1% | +24.4% | |
| Q3 2024 | +0.3% | -0.6% | -4.2% | |
| Q2 2024 | -17.2% | -14.1% | +4.6% | |
| Q1 2024 | -8.6% | -8.8% | +4.9% | |
| Q4 2023 | +34.6% | +37.9% | +50.9% | |
| Q3 2023 | -23.1% | -18.6% | -5.6% | |
| Q2 2023 | +11.1% | +4.4% | -19.8% | |
| Q1 2023 | -8.4% | -12.2% | -13.8% | |
| Q4 2022 | -27.9% | -27.9% | -40.6% | |
| Q3 2022 | -1.6% | +8.4% | +4.5% | |
| Q2 2022 | -8.9% | -8.2% | -25.7% | |
| Q1 2022 | +23.7% | +42.2% | +53.6% | |
| Q4 2021 | +4.1% | +2.3% | +2.8% | |
| Q3 2021 | -5.4% | -7.2% | -24.1% | |
| Q2 2021 | +16.4% | +13.4% | +12.3% | |
| Q1 2021 | -8.5% | -14.9% | -10.4% | |
| Q4 2020 | +2.1% | +12.4% | +21.7% | |
| Q3 2020 | +2.6% | +0.6% | +19.5% | |
| Q2 2020 | +13.9% | +18.0% | +7.0% | |
| Q1 2020 | +1.6% | +5.8% | +5.5% | |
| Q4 2019 | +1.8% | +1.4% | -7.7% | |
| Q3 2019 | -4.1% | -4.9% | -3.3% | |
| Q2 2019 | +0.0% | +0.0% | -0.6% | |
| Q1 2019 | +0.0% | +0.0% | +0.3% | |
| Q4 2018 | +0.6% | +0.7% | +1.3% | |
| Q3 2018 | +0.3% | +0.1% | +0.4% | |
| Q2 2018 | +0.0% | +0.3% | +0.1% | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro